Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Cipla Limited
WARNING LETTER
•Cipla Limited•February 17, 2023

Cipla Limited – FDA Warning Letter, Feb 17, 2023

Record Details

The FDA issued a Warning Letter to Cipla Limited, Mumbai, India, following an inspection from February 6-17, 2023, at their Indore manufacturing facility. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations (21 CFR parts 210 and 211), rendering their drug products adulterated. Additionally, the firm failed to submit a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) Field Alert Report (FAR) within three working days, as required by 21 CFR 314.81(b)(1)(ii).

Key violations include: 1. **Inadequate Investigations (21 CFR 211.192):** Cipla failed to thoroughly investigate approximately 3,000 complaints (April 2020-December 2022) for Albuterol Sulfate Inhalation Aerosol, primarily "no spray" or "empty/less weight." Investigations were prolonged, lacked timely CAPAs, and did not extend to all potentially affected batches. Despite identifying defective metered dose inhaler (MDI) valves causing drug delivery blockage, the firm classified the issue as "Non-Critical," did not submit a FAR, and took no market action, leaving impacted batches on the market. Subsequent complaints (January-August 2023) with similar issues further indicated unresolved problems. 2.

Company
Cipla Limited
Inspection date
February 17, 2023
Product type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Francis Godwin (Director)
  • Anita Narula (Compliance Officer - CDER/OC/OMQ)
View Company Profile

ID · 4a179ebd-255d-4805-a6d2-4e500633be4e

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 314.81(b)(1)(ii)21 CFR 211.19221 CFR 211.113(b)21 CFR 211.22(d)21 CFR 211.34FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Cipla Limited
  • 483 - 2026-08-25August 25, 2026
  • 483 - 2023-02-17February 17, 2023
  • 483 - 2022-07-01July 1, 2022
  • WARNING_LETTER - 2019-09-27September 27, 2019
  • 483 - 2018-04-13April 13, 2018

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Cipla Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.